AnaptysBio- And GSK-Partnered Immuno-Oncology Agent JEMPERLI Plus Chemotherapy Approved In The U.S. For dMMR/MSI-H Primary Advanced Or Recurrent Endometrial Cancer
Portfolio Pulse from Happy Mohamed
AnaptysBio, Inc. (NASDAQ:ANAB) and GSK have received FDA approval for their immuno-oncology treatment, JEMPERLI, in combination with chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer. This is the first such treatment approved in the frontline setting for this patient population. The approval could significantly drive JEMPERLI royalties. AnaptysBio is entitled to receive milestones and tiered royalties of 8% for net sales of JEMPERLI below $1 billion and 12% up to 25% of net sales above $1 billion.
July 31, 2023 | 5:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of JEMPERLI, a product developed by AnaptysBio and GSK, could significantly drive JEMPERLI royalties, positively impacting AnaptysBio's revenues.
The FDA approval of JEMPERLI, a product developed by AnaptysBio and GSK, for the treatment of advanced or recurrent endometrial cancer, represents a significant milestone for AnaptysBio. This could lead to increased revenues for the company through royalties, especially if net sales of JEMPERLI exceed $1 billion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
GSK, in partnership with AnaptysBio, has received FDA approval for JEMPERLI, which could potentially boost its revenues from the sales of this product.
The FDA approval of JEMPERLI, a product developed by GSK and AnaptysBio, for the treatment of advanced or recurrent endometrial cancer, represents a significant milestone for GSK. This could lead to increased revenues for the company from the sales of this product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100